| Cash flow (USD) | FY 2025 ended Dec 31, 2025 | FY 2024 ended Dec 31, 2024 | FY 2023 ended Dec 31, 2023 | FY 2022 ended Dec 31, 2022 | FY 2021 ended Dec 31, 2021 | FY 2020 ended Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Net income | 18.25B | 17.12B | 365.00M | 14.52B | 12.35B | 7.07B |
| Depreciation and amortization | 3.04B | 2.10B | 1.83B | 1.82B | 1.58B | 1.67B |
| Stock-based compensation | 820.00M | 761.00M | 645.00M | 541.00M | 479.00M | 441.00M |
| Cash from operations | 16.47B | 21.47B | 13.01B | 19.09B | 13.12B | 10.25B |
| Capital expenditure | -4.11B | -3.37B | -3.86B | -4.39B | -4.45B | -4.43B |
| Free cash flow | 12.36B | 18.10B | 9.14B | 14.71B | 8.67B | 5.82B |
| Acquisitions | -10.04B | 0 | 0 | 0 | -179.00M | -1.36B |
| Cash from investing | -13.74B | -7.73B | -14.08B | -4.96B | -16.42B | -9.44B |
| Dividends paid | -8.18B | -7.84B | -7.45B | -7.01B | -6.61B | -6.21B |
| Share buybacks | -5.08B | -1.31B | -1.35B | 0 | -840.00M | -1.28B |
| Net debt issued | 11.38B | 2.31B | 4.18B | -2.25B | 5.62B | 2.46B |
| Cash from financing | -1.92B | -7.03B | -4.81B | -9.12B | 3.10B | -2.83B |
| Net change in cash | 1.37B | 6.41B | -5.86B | 4.61B | 14.00M | -1.77B |
From Merck's 10-K and 10-Q filings with the SEC. Fiscal years are the company's own, so they may not match the calendar. A blank cell means the company did not report that line. New to this? Read cash flow or reading a 10-K.
Revenue, earnings, margins and balance sheet trends drawn by TradingView from its own data, so figures can differ slightly from the SEC table above.